Multisession Radiosurgery for Sellar and Parasellar @entity1653 : Long-term XXXX Growth Control and Visual Outcome.

@entity1 @entity227 @entity5 @entity25968 @entity1653 @entity1781 @entity74
BACKGROUND: Concern about @entity1781 ( @entity1781 ) has governed recent thinking about the role of radiation therapy in the treatment of @entity1653 involving the anterior optic pathways. Despite this concern, during the last few years, the use of radiosurgery for such lesions has increased steadily. OBJECTIVE: To define both the @entity5 control rate and the risk of @entity1781 over a long-term follow-up period in a large cohort of @entity1 treated with multisession radiosurgery. METHODS: The local control and visual outcome of 143 @entity1 who underwent multisession radiosurgery ( @entity25968 ) were evaluated. Neurological outcome was also analyzed. The data for the present study were obtained from a prospectively maintained database. RESULTS: The mean follow-up was 44 months (range, 12-113 months). All @entity1 underwent @entity25968 . The median prescription dose was 25 Gy delivered in 3 to 5 fractions. The prescription isodose, which typically encompassed at least 95% of the @entity5 , ranged from 65% to 86% (median, 80%). The mean @entity5 volume was 11.0 cm (range, 0.1-126.3 cm; median, 8 cm). The progression-free survival at 3, 5, and 8 years was 100%, 93%, and 90%, respectively. Compared with baseline, visual function improved in 36% of @entity1 , whereas 7.4% experienced a @entity227 (5.1% excluding the @entity1 with @entity74 ). CONCLUSION: Good local control rate and a low risk of @entity1781 indicate that @entity25968 is a safe and effective treatment option in cases of large @entity1653 . ABBREVIATIONS: AOP, anterior optic pathwayAVP, anterior visual pathwaymRS, multisession radiosurgeryPD, progressive diseaseRION, radiation-induced optic neuropathysRS, stereotactic radiosurgery.
